Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas

被引：0

作者：

Frakulli, Rezarta ^{[1
]}

Salvi, Fabrizio ^{[2
]}

Balestrini, Damiano ^{[2
]}

Parisi, Alessandro ^{[2
]}

Palombarini, Marcella ^{[3
]}

Cammelli, Silvia ^{[1
]}

Rocca, Michele ^{[4
]}

Salone, Mariacristina ^{[4
]}

Longhi, Alessandra ^{[5
]}

Ferrari, Stefano ^{[5
]}

Morganti, Alessio G. ^{[1
]}

Frezza, Giovanni ^{[2
]}

机构：

[1] Univ Bologna, Dept Expt Diagnost & Specialty Med, Radiat Oncol Ctr, I-40138 Bologna, Italy

[2] Bellaria Hosp, Radiat Oncol Unit, Bologna, Italy

[3] Bellaria Hosp, Med Phys Unit, Bologna, Italy

[4] Rizzoli Orthopaed Inst, Gen & Thorac Surg, Bologna, Italy

[5] Rizzoli Orthopaed Inst, Dept Oncol, Bologna, Italy

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 10期

关键词：

SBRT; sarcoma; lung metastases; PULMONARY METASTASES; SBRT;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The purpose of this study was to evaluate local control and toxicity in a group of patients treated with stereotactic body radiotherapy (SBRT) for lung metastases (LM) from bone and soft tissue sarcomas. Patients and Methods: From October 2010 to July 2014, patients with LM from sarcomas not suitable for surgery were treated with daily cone-beam computed tomography-guided SBRT. The dose administered ranged from 30 to 60 Gy in 3-8 fractions. Acute and late toxicity were scored according to Common Terminology Criteria for Adverse Events version 4.0. Results: A total of 24 patients with 68 LM from sarcomas were treated with SBRT. The median follow-up after SBRT was 17 months (range=11-51 months). Two-year actuarial lesion local control and overall survival were 85.9% and 66.4%, respectively. No G3 or greater acute and late toxicities were observed. Conclusion: SBRT is a safe and effective treatment for LM from sarcoma and might be used as an alternative option in patients unfit for surgery.

引用

页码：5581 / 5586

页数：6

共 50 条

[21] Outcomes and toxicity of radiotherapy for refractory bone and soft tissue sarcomas
Doi, Hiroshi
Oh, Ryoong-Jin
Miura, Hideharu
Masai, Norihisa
Shiomi, Hiroya
Inoue, Toshihiko
MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (01) : 83 - 88
[22] Radiotherapy of soft tissue sarcomas
Budach, W.
Matuschek, C.
ONKOLOGE, 2014, 20 (11): : 1113 - 1120
[23] Soft-Tissue sarcomas: Diagnosis and treatment from the plastic reconstructive surgeon perspective
Kapukaya, Rana
TURKISH JOURNAL OF PLASTIC SURGERY, 2022, 30 (04) : 115 - 120
[24] Growth rate of lung metastases and S-phase fraction as determined by flow cytometry from the primary tumour in 25 patients with bone or soft-tissue sarcomas
Blomqvist, C
Huuhtanen, R
Pan, Y
Wiklund, T
Tarkkanen, M
Virolainen, M
Tribukait, B
BRITISH JOURNAL OF CANCER, 1996, 73 (12) : 1556 - 1559
[25] Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus
Keedy, Vicki L.
ONCOTARGETS AND THERAPY, 2012, 5 : 153 - 159
[26] Imaging of soft-tissue sarcomas.
Varma D.G.
Current Oncology Reports, 2000, 2 (6) : 487 - 490
[27] Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma
Loi, Mauro
Duijm, Marloes
Baker, Sarah
Rossi, Linda
Grunhagen, Dirk
Verhoef, Cornelis
Nuyttens, Joost
RADIOLOGIA MEDICA, 2018, 123 (11): : 871 - 878
[28] Emerging Therapies for Soft-Tissue Sarcomas
Levard, Alice
Tassy, Louis
Cassier, Philippe A.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (05) : 1063 - 1078
[29] Immunity against soft-tissue sarcomas
Robert G. Maki
Current Oncology Reports, 2003, 5 (4) : 282 - 287
[30] Distant skin and soft tissue metastases from sarcomas
Rao, UNM
Hanan, SH
Lotze, MT
Karakousis, CP
JOURNAL OF SURGICAL ONCOLOGY, 1998, 69 (02) : 94 - 98

← 1 2 3 4 5 →